Slingshot members are tracking this event:
US FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 05, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fda Approval, Daklinza, Daclatasvir, Genotype 1, Genotype 3, Chronic Hepatits C